The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

British Journal of Haematology

Volumn 136, Issue 6, 2007, Pages 814-828

  Stapnes, Camilla ^a,b   Døskeland, Anne P ^a   Hatfield, Kimberley ^a,b   Ersvær, Elisabeth ^a,b   Ryningen, Anita ^a,b   Lorens, James B ^a   Gjertsen, Bjørn Tore ^a,b   Bruserud, Øystein ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute myeloid leukaemia; Bortezomib; Chemotherapy; In vitro effects; PR 171; Proteasome inhibition

Indexed keywords

BORTEZOMIB; CD34 ANTIGEN; CHYMOTRYPSIN; CYTARABINE; CYTOKINE; IDARUBICIN; PR 171; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CLONOGENESIS; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROTEASE INHIBITORS; PYRAZINES;

EID: 33847410207     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06504.x     Document Type: Article

References (40)

1. Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S. & Elliott, P.J. (1999) Proteasome inhibitors: a novel class of potent and effective anti-tumor agents. Cancer Research, 59, 2615-2622.
2. Anderson, J.E., Kopecky, K.J., Willman, C.L., Head, D., O'Donnell, M.R., Luthardt, F.W., Norwood, T.H., Chen, I.M., Balcerzak, S.P., Johnson, D.B. & Appelbaum, F.R. (2002) Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood, 100, 3869-3876.
3. Bonnet, D. (2005) Cancer stem cells: AMLs show the way. Biochemical Society Transactions, 33, 1531-1533.
4. Braun, T., Carvalho, G., Coquelle, A., Vozenin, M.C., Lepelley, P., Hirsch, F., Kiladjian, J.J., Ribrag, V., Fenaux, P. & Kroemer, G. (2006a) NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood, 107, 1156-1165.
5. Braun, T., Carvalho, G., Fabre, C., Grosjean, J., Fenaux, P. & Kroemer, G. (2006b) Targeting NF-kappaB in hematologic malignancies. Cell Death and Differentiation, 13, 748-758.
6. Bruserud, O., Gjertsen, B.T. & Von Volkman, H.L. (2000) In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines. Journal of Hematotherapy & Stem Cell Research, 9, 923-932.
7. Bruserud, O., Gjertsen, B.T., Foss, B. & Huang, T.S. (2001) New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of AML cells - the present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells, 19, 1-11.
8. Bruserud, O., Hovland, R., Wergeland, L., Huang, T.S. & Gjertsen, B.T. (2003) Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica, 88, 416-428.
9. Bruserud, O., Ryningen, A., Wergeland, L., Glenjen, N.I. & Gjertsen, B.T. (2004) Osteoblasts increase proliferation and release of proangiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica, 89, 391-402.
10. Bruserud, O., Stapnes, C., Tronstad, K.J., Ryningen, A., Anensen, N. & Gjertsen, B.T. (2006) Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opinion on Therapeutic Targets, 10, 51-68.
11. Bruserud, O., Ryningen, A., Olsnes, A.M., Stordrange, L., Oyan, A.M., Kalland, K.H. & Gjertsen, B.T. (2007) Subclassification of acute myelogenous leukemia patients based on chemokine respensiveness and constitutive chemokine release by the leukemia cells. Haematologica, in press.
12. Burger, A.M. & Seth, A.K. (2004) The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. European Journal of Cancer, 40, 2217-2229.
13. Demo, S.D., Buchholtz, T.J., Laidig, G.J., Parlati, F., Shenk, K.D., Smyth, M.S., Sullivan, C.M., Sun, C.M., Vallone, M.K., Woo, T. & Bennett, M.K. (2005) Biochemical and cellular characterization of the novel proteasome inhibitor PR-171. Blood, 106, 455a.
14. Glenjen, N., Ersvaer, E., Ryningen, A. & Bruserud, O. (2004) In vitro effects of native human acute myelogenous leukemia blasts on fibroblasts and osteoblasts. International Journal of Cancer, 111, 858-867.
15. Glickman, M.H. & Ciechanover, A. (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiological Reviews, 82, 373-428.
16. Glickman, M.H. & Raveh, D. (2005) Proteasome plasticity. FEBS Letters, 579, 3214-3223.
17. Guo, W., Lasky, J.L. & Wu, H. (2006) Cancer stem cells. Pediatric Research, 59, 59R-64R.
18. Guzman, M.L., Swiderski, C.F., Howard, D.S., Grimes, B.A., Rossi, R.M., Szilvassy, S.J. & Jordan, C.T. (2002) Preferential induction of apoptosis for primary human leukaemic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 99, 16220-16225.
19. Hershko, A. (2005) The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death and Differentiation, 12, 1191-1197.
20. Horton, T.M., Gannavarapu, A., Blaney, S.M., D'Argenio, D.Z., Plon, S.E. & Berg, S.L. (2006) Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemotherapy and Pharmacology, 58, 13-23.
21. Iversen, P.O., Hart, P.H., Bonder, C.S. & Lopez, A.F. (1997) Interleukin (IL)-10, but not IL-4 or IL-13, inhibits cytokine production and growth in juvenile myelomonocytic leukemia cells. Cancer Research, 57, 476-480.
22. Kraus, M., Ruckrich, T., Reich, M., Gogel, J., Beck, A., Kammer, W., Berkers, C.R., Burg, D., Overkleeft, H., Ovaa, H. & Driessen, C. (2007) Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia, 1, 84-92.
23. Melino, G. (2005) Discovery of the ubiquitin proteasome system and its involvement in apoptosis. Cell Death and Differentiation, 12, 1155-1157.
24. Minderman, H., Zhou, Y., O'Loughlin, K.L. & Baer, M.R. (2006) Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemotherapy and Pharmacology.
25. Nencioni, A., Grunebach, F., Patrone, F., Ballestrero, A. & Brossart, P. (2007) Proteasome inhibitors: antitumor effects and beyond. Leukemia, 1, 30-36.
26. Orlowski, R.Z. (2005) The ubiquitin proteasome pathway from bench to bedside. Hematology; The American Society of Hematology Educational Program Book, 1, 220-225.
27. Palombella, V.J., Conner, E.M., Fuseler, J.W., Destree, A., Davis, J.M., Laroux, F.S., Wolf, R.E., Huang, J., Brand, S., Elliott, P.J., Lazarus, D.D., McCormack, T., Parent, L., Stein, R., Adams, J. & Grisham, M.B. (1998) Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proceedings of the National Academy of Sciences of the United States of America, 95, 15671-15676.
28. Rajkumar, S.V., Richardson, P.G., Hideshima, T. & Anderson, K.C. (2005) Proteasome inhibition as a novel therapeutic target in human cancer. Journal of Clinical Oncology, 23, 630-639.
29. Reya, T., Morrison, S.J., Clarke, M.F. & Weissman, I.L. (2001) Stem cells, cancer, and cancer stem cells. Nature, 414, 105-111.
30. Richardson, P. (2003a) Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treatment Reviews, 29(Suppl. 1), 33-39.
31. Richardson, P.G. (2003b) Bortezomib: a novel therapy approved for multiple myeloma. Clinical Advances in Hematology & Oncology, 1, 596-600.
32. Ryningen, A., Wergeland, L., Glenjen, N., Gjertsen, B.T. & Bruserud, O. (2005) In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8. Leukemia Research, 29, 185-196.
33. Ryningen, A., Ersvaer, E., Oyan, A.M., Kalland, K.H., Vintermyr, O.K., Gjertsen, B.T. & Bruserud, O. (2006) Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90. Leukemia Research, 30, 1531-1540.
34. Smith, M., Barnett, M., Bassan, R., Gatta, G., Tondini, C. & Kern, W. (2004) Adult acute myeloid leukaemia. Critical Reviews in Oncology/ Hematology, 50, 197-222.
35. Spano, J.P., Bay, J.O., Blay, J.Y. & Rixe, O. (2005) Proteasome inhibition: a new approach for the treatment of malignancies. Bulletin du Cancer, 92, E61-E66.
36. Sutheesophon, K., Kobayashi, Y., Takatoku, M.A., Ozawa, K., Kano, Y., Ishii, H. & Furukawa, Y. (2006) Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukaemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematologica, 115, 78-90.
37. Wheatley, K, Burnett, A.K., Goldstone, A.H., Gray, R.G., Hann, I.M., Harrison, C.J., Rees, J.K., Stevens, R.F. & Walker, H. (1999) A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia from MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. British Journal of Haematology, 107, 69-79.
38. Yan, L., Anderson, G.M., DeWitte, M. & Nakada, M.T. (2006) Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. European Journal of Cancer, 42, 793-802.
39. Yu, C., Rahmani, M., Conrad, D., Subler, M., Dent, P. & Grant, S. (2003) The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood, 102, 3765-3774.
40. Zhang, H.G., Wang, J., Yang, X., Hsu, H.C. & Mountz, J.D. (2004) Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene, 23, 2009-2015.